High-content phenotypic and pathway profiling to advance drug discovery in diseases of unmet need.

Abstract excerpt

Conventional thinking in modern drug discovery postulates that the design of highly selective molecules which act on a single disease-associated target will yield safer and more effective drugs. However, high clinical attrition rates and the lack of progress in developing new effective treatments for many important diseases of unmet therapeutic need challenge this hypothesis. This assumption also impinges upon...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Disease
• Share to Drug Discovery
• Share to Pharmaceutical Preparations